Solventum (SOLV) Q1 2026 earnings review
Adjusted Earnings Resilience Masks Severe Cash Burn and GAAP Margin Collapse
Solventum delivered a highly bifurcated Q1 2026. On an adjusted basis, the company beat expectations: organic sales grew a stable 2.1% and Adjusted EPS rose 10.6% to $1.48. However, the GAAP reality was ugly. Net Income collapsed 90.5% to just $13 million, crushed by $163 million in spin-off costs and $41 million in restructuring. The operational cash drain was severe, with Free Cash Flow reversing to $(273) million. While Health Information Systems (HIS) accelerated brilliantly, MedSurg margins were compressed. Management affirmed full-year guidance, implying they expect a massive recovery in cash generation over the next three quarters.
🐂 Bull Case
HIS organic growth accelerated to 4.7%, with segment operating margins surging 500 bps YoY to 38.1%. The segment is proving highly defensible and profitable.
Despite ongoing macro headwinds from tariffs and inflation, programmatic savings drove an 80 bps increase in both GAAP and Adjusted Gross Margins.
🐻 Bear Case
Free Cash Flow of $(273)M is a massive hole. To hit the affirmed ~$200M FY guidance, the company must generate roughly $473M over the next three quarters—a steep climb.
MedSurg, the largest segment, saw its operating margin drop from 17.8% to 13.1%, bearing the brunt of separation costs and supply chain inefficiencies.
⚖️ Verdict: ⚪
Neutral. The core commercial engine is stable and non-GAAP metrics look solid, but the extreme cash burn and massive gap between reported and adjusted earnings make this a 'show me' story for the remainder of the year.
Key Themes
Cash Flow Reversing Opposite to Net Income
A major red flag appeared in cash generation. Operating Cash Flow reversed sharply to $(189)M, moving in the complete opposite direction of the $13M positive Net Income. This disconnect was driven by a $151M outflow for accrued compensation and a $100M payout to related parties (legacy 3M ties). This cash drag heavily strains liquidity while separation activities continue.
Health Information Systems (HIS) Outperformance
HIS is the clear star of the portfolio. Organic sales growth is accelerating (from 3.2% in 25Q4 to 4.7% in 26Q1). More impressively, segment operating income jumped to $130 million, yielding a 38.1% margin (up from 33.1% a year ago). The adoption of AI-driven autonomous coding and RCM software continues to yield high-margin recurring revenue.
Gross Margin Expansion Amidst Macro Headwinds
A key positive driver for the quarter was gross margin resilience. GAAP and Adjusted Gross Margins both increased by 80 bps (Adjusted reaching 56.4%). Management successfully utilized programmatic savings and favorable portfolio mix to completely offset stated macro headwinds from tariffs and inflation.
Infection Prevention & Surgical Solutions (IPSS) Decelerating
IPSS organic growth has virtually stalled, decelerating to just +0.6% in 26Q1. This represents a severe drop from previous quarters (e.g., +8.2% in 25Q1). As a crucial volume contributor within MedSurg, this stagnation requires immediate commercial intervention to prevent overall top-line drag.
Widening GAAP to Non-GAAP Disconnect
There is a glaring contradiction in the P&L: while gross margins improved by 80 bps, GAAP operating margin collapsed by 330 bps to a mere 4.0%. The culprit is a massive layer of below-the-line expenses, including $163M in spin-off costs and $41M in restructuring ('Transform for the Future' program). Until these costs roll off, true earnings quality remains low.
Expanding Footprint for Innovation Pipeline
Solventum is aggressively building its standalone physical footprint to drive future product launches. The company opened a new 250,000 square foot flagship R&D center in Eagan, Minnesota, and completed a 200,000 square foot manufacturing expansion in Brookings, South Dakota. This infrastructure investment is a critical driver for maintaining the high 'vitality index' of new products promised by management.
Other KPIs
Decelerating. Organic growth came in at a sluggish 1.2%, down from 3.2% in 25Q4. While Advanced Wound Care grew a respectable 2.1%, it was dragged down by the near-flat (0.6%) performance in Infection Prevention and Surgical Solutions.
Accelerating significantly. SG&A rose 7.5% YoY, vastly outpacing the organic revenue growth of 2.1%. This line item absorbed the heavy lifting of separation activities and 'Transform for the Future' implementation costs, acting as the primary anchor on GAAP operating margins.
Guidance
Stable. The affirmed guidance implies that the 2.1% growth achieved in 26Q1 is exactly the run-rate expected for the remainder of the year. Excluding approximately 100 bps of SKU exit impacts, the underlying growth rate is expected to be 3.0% to 4.0%.
Accelerating compared to 25FY. Achieving the high end ($6.60) implies healthy margin execution through the rest of the year, relying on programmatic savings and pricing to offset the $100M-$120M tariff headwinds previously forecasted.
Reversing significantly. With 26Q1 printing $(273) million, achieving this annual target requires generating roughly $473 million in positive free cash flow over the next three quarters. This assumes a sharp drop-off in transition exit payments and an unwind of working capital build.
Key Questions
Bridging the Free Cash Flow Deficit
Given the $(273) million FCF hole in Q1, what specific working capital reversals and step-downs in separation costs give you confidence in generating the required ~$473 million in Q2-Q4 to hit your ~$200 million annual target?
IPSS Stagnation
Infection Prevention and Surgical Solutions organic growth decelerated to just 0.6%. Is this driven by competitive losses, market softness, or lingering ERP disruption, and what is the specific commercial plan to re-accelerate this unit?
Margin Divergence and Stand-up Costs
Adjusted margins are holding up well, but GAAP margins are heavily pressured by SG&A. When exactly do the dual 'Transform for the Future' and 3M separation costs peak, and when will we see GAAP and Non-GAAP profitability begin to converge?